Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer
Dr. Matthew Weiss presents data on patient organoids & cancer care at the American Surgical Association annual meeting
The Blockchain-based solution was awarded the 2021 Bionow Technical Service Award
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
The FDA decision is primarily informed by the positive results of a proof-of-concept, Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg RSVpreF in a human viral challenge model in healthy adults 18 to 50 years of age
Subscribe To Our Newsletter & Stay Updated
